Articles with public access mandates - Samuel MurrayLearn more
Not available anywhere: 3
High response rate and durability driven by HLA genetic diversity in patients with kidney cancer treated with lenvatinib and pembrolizumab
CH Lee, RG DiNatale, D Chowell, C Krishna, V Makarov, C Valero, ...
Molecular Cancer Research 19 (9), 1510-1521, 2021
Mandates: US Department of Defense, US National Institutes of Health
A Carboxy Terminal BMP/TGF‐β Binding Site in Secreted Phosphoprotein 24 kD Independently Affects BMP‐2 Activity
H Tian, CS Li, KW Zhao, JC Wang, MEL Duarte, CL David, K Phan, E Atti, ...
Journal of cellular biochemistry 116 (4), 667-676, 2015
Mandates: US National Institutes of Health, US Department of Veterans Affairs
PD40-05 NEOADJUVANT IMMUNOTHERAPY IN PATIENTS WITH RENAL CELL CARCINOMA UNDERGOING NEPHRECTOMY
K Attalla, M Carlo, S Gupta, S Patil, D Coskey, S Murray, R Kotecha, ...
Journal of Urology 206 (Supplement 3), e675-e676, 2021
Mandates: US National Institutes of Health
Available somewhere: 9
Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting
G Theron, J Peter, R van Zyl-Smit, H Mishra, E Streicher, S Murray, ...
American journal of respiratory and critical care medicine 184 (1), 132-140, 2011
Mandates: Canadian Institutes of Health Research
Genotype Misclassification in Genetic Association Studies of the rs1042522 TP53 (Arg72Pro) Polymorphism: A Systematic Review of Studies of Breast, Lung …
IJ Dahabreh, CH Schmid, J Lau, V Varvarigou, S Murray, TA Trikalinos
American journal of epidemiology 177 (12), 1317-1325, 2013
Mandates: US National Institutes of Health
Comprehensive molecular characterization and response to therapy in fumarate hydratase–deficient renal cell carcinoma
JP Gleeson, I Nikolovski, R Dinatale, M Zucker, A Knezevic, S Patil, Y Ged, ...
Clinical Cancer Research 27 (10), 2910-2919, 2021
Mandates: US National Institutes of Health
Multicenter evaluation of the fully automated PCR-based Idylla EGFR mutation assay on formalin-fixed, paraffin-embedded tissue of human lung cancer
SM Evrard, E Taranchon-Clermont, I Rouquette, S Murray, S Dintner, ...
The Journal of Molecular Diagnostics 21 (6), 1010-1024, 2019
Mandates: Government of Spain
Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
DR Feldman, Y Ged, CH Lee, A Knezevic, AM Molina, YB Chen, J Chaim, ...
Cancer 126 (24), 5247-5255, 2020
Mandates: US National Institutes of Health
Matched molecular profiling of cell-free DNA and tumor tissue in patients with advanced clear cell renal cell carcinoma
RR Kotecha, E Gedvilaite, R Ptashkin, A Knezevic, S Murray, I Johnson, ...
JCO Precision Oncology 6, e2200012, 2022
Mandates: US Department of Defense, US National Institutes of Health, Robert Wood …
Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
MF Alvisi, M Ganzinelli, H Linardou, E Caiola, G Lo Russo, FL Cecere, ...
Journal of clinical medicine 9 (8), 2438, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab
CH Lee, RG DiNatale, D Chowell, C Krishna, V Makarov, C Valero, ...
Molecular cancer research: MCR 19 (9), 1510, 2021
Mandates: US Department of Defense, US National Institutes of Health
Single-arm, open label prospective trial to assess prediction of the role ofáERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
M Ganzinelli, H Linardou, MF Alvisi, E Caiola, GL Russo, FL Cecere, ...
ESMO open 6 (1), 100034, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
Publication and funding information is determined automatically by a computer program